Skip to content
value.today

VeraDermics, Inc

🇺🇸 San Antonio, Texas, USAHealth CareFounded 2021
Total raised
$269 M
5 rounds on record
Latest round
$30 M
May 2026
First round on record
Sep 2021
Today
Went public
See the company page

VeraDermics, Inc is listed today as Veradermics, Inc: market value, financials and filings are on its company page.

Funding rounds

5 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of VeraDermics, Inc
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2026$30 MNo. 5$10 to $50 million

VeraDermics, Inc: Raise no. 5, May 2026

Investors in this round

2 investors had bought by the notice of May 15, 2026: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for VeraDermics, Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$30 M of $30 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,800,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dominic Carrano · Executive Officer
  • Mark Neumann · Executive Officer
  • Michael Greco · Executive Officer
  • Reid Waldman · Executive Officer, Director
  • Tim Durso · Executive Officer
  • David Friedman · Director
  • Jane Grant-Kels · Director
  • John Childs · Director
  • Katarina Pance · Director
  • Patrick Enright · Director
  • Vladimir Coric · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • JEFFERIES LLC (CRD 2347) · New York, New YorkSold in all US states
  • LEERINK PARTNERS LLC (CRD 39011) · Boston, MassachusettsSold in all US states
  • CITIGROUP GLOBAL MARKETS INC. (CRD 7059) · New York, New YorkSold in all US states
  • CANTOR FITZGERALD & CO. (CRD 134) · New York, New YorkSold in all US states
  • LIFESCI CAPITAL (CRD 168404) · New York, New YorkSold in all US states
  • NEEDHAM & COMPANY, LLC (CRD 16360) · New York, New YorkSold in all US states

Signed by Reid Waldman, Chief executive officer. Source: SEC Form D, newest notice filed May 15, 2026. Read the notice at the SEC.

optionsSEC
Oct 2025$135 MNo. 4$50 to $250 million

VeraDermics, Inc: Raise no. 4, Oct 2025

Investors in this round

40 investors had bought by the notice of Oct 28, 2025: 40 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for VeraDermics, Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$135 M of $150 M offered; $15 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Reid Waldman · Executive Officer, Director
  • Amanda Birdsey-Benson · Director
  • Jane Grant-Kels · Director
  • John Childs · Director
  • Katarina Pance · Director
  • Patrick Enright · Director
  • Vladimir Coric · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Reid Waldman, Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 28, 2025. Read the notice at the SEC.

equitySEC
Nov 2024$67 MNo. 3$50 to $250 million

VeraDermics, Inc: Raise no. 3, Nov 2024

Investors in this round

40 investors had bought by the notice of Dec 10, 2024: 40 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for VeraDermics, Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$67 M of $75 M offered; $8 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Reid W. Waldman · Executive Officer, Director
  • Amanda W. Birdsey-Benson · Director
  • Christopher W. Eklund · Director
  • Jane W. Grant-Kels · Director
  • John W. Childs · Director
  • Patrick W. Enright · Director
  • Vladimir W. Coric · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Reid Waldman, Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 10, 2024. Read the notice at the SEC.

equitySEC
Apr 2023$15 MNo. 2$10 to $50 million

VeraDermics, Inc: Raise no. 2, Apr 2023

Investors in this round

16 investors had bought by the notice of May 1, 2023: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for VeraDermics, Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$15 M of $15 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Reid Waldman · Executive Officer, Director
  • Timothy Durso · Executive Officer, Director
  • Jane W. Grant-Kels · Director
  • John W. Childs · Director
  • Vladimir Coric · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Timothy Durso, President. Source: SEC Form D, newest notice filed May 1, 2023. Read the notice at the SEC.

equitySEC
Sep 2021$22 MNo. 1$10 to $50 million

VeraDermics, Inc: Raise no. 1, Sep 2021

Investors in this round

41 investors had bought by the notice of Oct 7, 2021: 41 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for VeraDermics, Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$22 M of $22 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Reid Waldman · Executive Officer, Director
  • Timothy Durso · Executive Officer, Director
  • Jane W. Grant-Kels · Director
  • John W. Childs · Director
  • Vladimir Coric · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Timothy Durso, President. Source: SEC Form D and 1 amendment, newest notice filed Oct 7, 2021. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • VeraDermics, Inc chose not to state its revenue in its newest notice of a funding round (May 2026).

    SEC Form D · May 2026

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · May 2026

That is all the official record says: VeraDermics, Inc has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of VeraDermics, Inc are on record.

Investors#

8 named in official filings. Open an investor to see everything it has backed.

Investors in VeraDermics, Inc
InvestorKindAmountRoundRoleSource
Jane M. Grant-KelsPersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2026)SEC Form 3
Longitude 103.8 East, L.P.Fund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2026)SEC Form 3
Longitude 103.8 East Partners, LLCFund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2026)SEC Form 3
Longitude Capital Partners V, LLCFund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2026)SEC Form 3
Longitude Venture Partners V, L.P.Venture capitalnot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2026)SEC Form 3
Reid Alexander WaldmanPersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2026)SEC Form 3
Timothy August DursoPersonnot statednot statedHeld Series A preferred stock (Form 3, 2026)SEC Form 3
Vlad CoricPersonnot statednot statedHeld Series C preferred stock, director (Form 3, 2026)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 41 investors.

Largest shareholders today

Institutions holding Veradermics, Inc shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by VeraDermics, Inc
NameRoleNamed in
Dominic CarranoExecutive officerMay 2026
Mark NeumannExecutive officerMay 2026
Michael GrecoExecutive officerMay 2026
Reid WaldmanExecutive officerMay 2026
Tim DursoExecutive officerMay 2026
Reid W. WaldmanExecutive officerDec 2024
Timothy DursoExecutive officerMay 2023
David FriedmanDirectorMay 2026
Jane Grant-KelsDirectorMay 2026
John ChildsDirectorMay 2026
Katarina PanceDirectorMay 2026
Patrick EnrightDirectorMay 2026
Reid WaldmanDirectorMay 2026
Vladimir CoricDirectorMay 2026
Amanda Birdsey-BensonDirectorOct 2025
Amanda W. Birdsey-BensonDirectorDec 2024
Christopher W. EklundDirectorDec 2024
Jane W. Grant-KelsDirectorDec 2024
John W. ChildsDirectorDec 2024
Patrick W. EnrightDirectorDec 2024
Reid W. WaldmanDirectorDec 2024
Vladimir W. CoricDirectorDec 2024
Timothy DursoDirectorMay 2023

Went public since 2026. Its SEC number is that of a company listed on a stock exchange.